臨床婦人科産科65巻7号

2011年07月発行

今月の臨床 卵巣がん─最新の治療戦略 初回治療 3．ファーストラインの化学療法

3）ベバシズマブ（bevacizumab）の追加

著者： 杉山徹¹

所属機関： ¹岩手医科大学産科婦人科

ページ範囲：P.884 - P.890

　卵巣癌治療の臨床研究において国際コンセンサスが得られているのは，（1）dose-dense paclitaxel（dd─TXL）と（2）腹腔内化学療法（IP）であり，これに分子標的薬を加えた臨床試験が加速している．現時点で大規模なランダム化試験（RCT）でエビデンスが示されている分子標的薬はベバシズマブのみである．ベバシズマブをTC療法と併用し，さらにベバシズマブでの維持療法を行うことで無増悪生存期間（PFS）の改善が示されたが，全生存期間（OS）の改善はなく，費用対効果が現実的な課題である．

参考文献

1） 日本婦人科学会・編．卵巣がん治療ガイドライン2010年版，金原出版，東京，2010

2） Ozols RF, Bundy BN, Greer BE, et al : Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer : a Gynecologic Oncology Group study. J Clin Oncol 21 : 3194─3200, 2003（GOG 158）

3） Du Bois A, Luck HJ, Meier W, et al : A randomized clinical trial of cisplatin／paclitaxel versus carboplatin／paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95 : 1320─1329, 2003（AGO）

4） Bookman MA, Brady MF, McGuire WP et al : Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer : a phase III trial of the Gynecologic Cancer InterGroup. J Clin Oncol 27 : 1419─1425, 2009

5） Markman M, Liu PY, Wilczynski S, et al : Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy : A Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21 : 2460─2465, 2003（GOG 178）

6） Pecorelli S, Favalli G, Gadducci A, et al : Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel／platinum-based chemotherapy : final results of the After─6 Protocol 1. J Clin Oncol 1 : 4642─4648, 2009

7） Katsumata N, Yasuda M, Takahashi F, et al : Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer : a phase 3, open-label, randomized controlled trial. Lancet 374 : 1331─1338, 2009

8） Armstrong DK, Bundy B, Wenzel L, et al : Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354 : 34─43, 2006（GOG 172）

9） Neufeld G, Cohen T, Gengrinovitch S, et al : Vascular endothelial growth factor（VEGF）and its receptors. FASEB J 13 : 9─22, 1999

10） Yoneda J, Kuniyasu H, Crispens MA, et al : Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 90 : 447─454, 1998

11） Dvorak HF : Vascular permeability factor／vascular endothelial growth factor : a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20 : 4368─4380, 2002

12） Hu L, Hofmann J, Zaloudek C, et al : Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 161 : 1917─1924, 2002

13） Burger RA, Sill MW, Monk BJ, et al : Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer : A Gynecologic Oncology Group Study. J Clin Oncol 25 : 5165─5171, 2007

14） Cannistra SA, Matulonis UA, Penson RT, et al : Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25 : 5180─5186, 2007

15） Han E, Monk BJ : What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer. Gynecol Oncol 105 : 3─6, 2007

16） Sweeney CJ, Miller KD, Sissons SE, et al : The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2─methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 61 : 3369─3372, 2001

17） Garcia AA, Hirte H, Fleming G, et al : Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer : a trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia. J Clin Oncol 26 : 76─82, 2008

18） Burger RA, Brady MF, Bookman MA, et al : Phase III trial of bevacizumab（BEV）in the primary treatment of advanced epithelial ovarian cancer（EOC）, primary peritoneal cancer（PPC）, or fallopian tube cancer（FTC） : A Gynecologic Oncology Group study. Proc Am Soc Clin Oncol 28 : 5s（LBA1）, 2010

19） Perren T, Swart AM, Pfisterer J, et al : ICON7 : A phase III Gynecologic Cancer InterGroup（GCIG）trial of adding bevacizumab to standard chemotherapy in women with newly diagnosed epithelial ovarian, primary peritoneal or fallopian tube cancer. ESMO 2010（Milan）